# S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations

## TL;DR

This paper updates guidelines for treating psoriasis, focusing on special cases like tuberculosis and inflammatory bowel diseases.

## Contribution

The paper introduces revised recommendations for managing psoriasis in comorbid conditions, including tuberculosis screening and new drug approvals.

## Key findings

- New recommendations for tuberculosis screening and therapy selection in psoriasis patients with latent TB.
- Risankizumab and guselkumab added as treatment options for inflammatory bowel diseases.
- Revisions to therapy guidance for patients with malignancy or viral hepatitis history.

## Abstract

The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon‐gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.